Vitamin D and Spondyloarthritis: Review of the Literature

Chiara Crotti1, Andrea Becciolini2, Martina Biggioggero1, Ennio Giulio Favalli2, *
1 Department of Clinical Sciences and Health Community, Division of Rheumatology, University of Milan, Gaetano Pini Institute, Milan, Italy
2 Department of Rheumatology, Gaetano Pini Institute, Milan, Italy

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 141
Abstract HTML Views: 131
PDF Downloads: 90
ePub Downloads: 83
Total Views/Downloads: 445
Unique Statistics:

Full-Text HTML Views: 102
Abstract HTML Views: 94
PDF Downloads: 61
ePub Downloads: 60
Total Views/Downloads: 317

© 2018 Crotti et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: ( This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Department of Rheumatology, Gaetano Pini Institute, Milan, Via Gaetano Pini, 9, 20122 Milan - Italy, Tel: +39 0258296421, Mobile: +39 3289659778, Fax: +39 0258296315; E-mail:



Spondyloarthritides (SpAs) encompass heterogeneous diseases sharing similar genetic background, pathogenic mechanisms, and phenotypic features. Vitamin D is essential for calcium metabolism and skeletal homeostasis. Some recent evidences reported supplemental functions of vitamin D, such as modulation of inflammatory reactions.


To analyze published data about a possible association between vitamin D and SpAs.


Vitamin D could play a role in immune reactions, influencing both immune and adaptive response. Vitamin D deficiency is more frequent in SpAs than in general population: an active and more severe disease infers patients’ mobility and reduces sunlight exposure. Quiescent inflammatory bowel disease, frequently associated with SpAs, could worsen vitamin D deficiency. All the parameters related to UVB exposure are the most important determinants for vitamin D status and need to be considered evaluating the vitamin D levels in SpAs.

Apart from musculoskeletal problems, patients affected by SpAs frequently suffer from other comorbidities, especially cardiovascular diseases and osteoporosis, and vitamin D status could have a relevance in this field. Bone is involved in SpAs with a dualistic role, coexisting trabecular bone resorption and new bone formation.

It seems rational to monitor vitamin D levels in SpA subjects and to target it to global health threshold.


Literature data were not completely in agreement about a possible relation between poor vitamin D status and onset or worse disease course of SpAs. In fact, these results come from cross-sectional studies, which affect our ability to infer causality. Therefore, large, randomized controlled trials are needed.

Keywords: Vitamin D, Spondyloarthritis, Reactive arthritis, Ankylosing spondylitis, Psoriatc arthritis, Enteropathic arthritis.


Spondyloarthritides (SpAs) encompass an interrelated group of heterogeneous clinical entities sharing similar genetic background, pathogenic mechanisms, and phenotypic features [1]. According to more recent classification, SpAs include axial-spondyloarthritis (axSpA) as both radiographic (Ankylosing Spondylitis [AS]) and non-radiographic (nr-axSpA) form, Psoriatic Arthritis (PsA), Reactive Arthritis (ReA), enteropathic arthritis, juvenile spondyloarthritis, and what has traditionally been referred to as undifferentiated seronegative arthritis [2]. The most important clinical manifestations of SpAs include inflammatory back pain, asymmetric peripheral oligoarthritis, predominantly in lower limbs, enthesitis, and sacroiliitis. Moreover, SpAs may also be complicated by extra-articular involvement, such as anterior uveitis, psoriasis, chronic inflammatory bowel disease, and osteoporosis [3, 4]. The latter may be related to both the hyper-production of pro-inflammatory cytokines such as Tumour Necrosis Factor alpha (TNF-α) and the role of vitamin D in affecting bone mineral density [5].

Vitamin D is a steroid hormone essential for the regulation of the calcium metabolism and skeletal homeostasis [6]. We distinguish two forms of vitamin D, cholecalciferol (vitamin D3), which derives from animals, and ergocalciferol (vitamin D2), that derives from plants, as well as vitamin D metabolites. The former comes from the endogenous conversion of 7-dehydrocholesterol into previtamin D in the skin upon ultraviolet B radiations, and the latter arises from the dietary intake. These precursors switch into the active form, 1,25-dihydroxy vitamin D3 (1,25(OH)2D) by successive hydroxylation, first in the liver to 25-hydroxy vitamin D (25(OH)D), subsequently in the kidneys to 1,25-dihydroxy vitamin D (1,25(OH)2D) [6, 7]. Due to the short half-life of 1,25(OH)2D, almost 4 hours, serum 25(OH)D is the metabolite used to measure the vitamin D status of individuals; in fact, it is the major circulating form with a long half-life (2-3 weeks) [8].

Recent evidence has shed light on the additional function of vitamin D, such as a significant role in the regulation of both adaptive and innate immune system, modulating inflammatory reactions [9-11]. Furthermore, epidemiological studies evidenced a higher prevalence of autoimmune and rheumatic diseases among people living at increasing latitude [12], where vitamin D deficiency, caused by reduced ultraviolet B exposure, may play a role. Moreover, several authors pointed out a potential association between a poor vitamin D status and different chronic illnesses, including cardiovascular disease, cancer, diabetes, and inflammatory diseases, such as multiple sclerosis, Inflammatory Bowel Disease (IBD), rheumatoid arthritis, and Ankylosing Spondylitis (AS) [6, 7, 13].

The aim of this review is to analyze data published on the relationship between vitamin D and SpAs, evaluating their potential epidemiological and pathophysiological connection and the implication for the management and treatment.


There is evidence that vitamin D exerts both inhibiting and activating actions in the immune system [9, 14]. Monocytes/macrophages and dendritic cells express 1-alpha-hydroxylase (Cytochrome P450 Family 27 Subfamily B -CYP27B-) Fig. (1). This gene can lead to the activation of 25(OH)D into the 1,25(OH)2D, which has inhibiting effects on dendritic cells, promoting monocyte to macrophage differentiation and producing immunosuppressant cytokines [15]. Moreover, macrophages stimulated by 1,25(OH)2D increase their phagocytic capacity and kill bacteria, particularly mycobacteria [16]. A genetic association has been found between a CYP27B1-gene and HLA-B27 anterior uveitis. A study compared three different groups: 159 HLA-B27-positive subjects with anterior uveitis, 138 HLA-B27-negative healthy controls and 100 HLA-B27 positive healthy controls. Steinwender and colleagues found a high prevalence of the G allele in HLA-B27 subjects with anterior uveitis compared to HLA-B27 positive healthy controls [17]. A few concerns about this study are related to the exclusion of the HLA-B27 negative controls, so it remains difficult to determine if this link is specific for HLA-B27 uveitis or only for uveitis. Another study by Mitulescu and coauthors, reported a negative correlation between vitamin D levels and acute anterior uveitis, linking altered vitamin D metabolism to the development of the ocular disease, which is an extra-articular manifestation often associated in SpAs [18].

Cells of the innate immune system, i.e. dendritic cells and macrophages, also express Vitamin D Receptor (VDR). Fok1, a genetic VDR polymorphism detected from genomic DNA from peripheral leukocytes, was associated with elevated acute phase reactant levels and spinal bone mass density in 71 axial SpA patients, compared to healthy controls [19]. Truthfully, such links between disease activity and VDR polymorphism have been described also in rheumatoid arthritis patients, suggesting that vitamin D metabolism can exert a broad spectrum of actions in inflammatory diseases.

Furhtermore, it has been described a genetic association between the Vitamin D-Binding Protein (VDBP) and some SpA phenotypes such as uveitis (OR 2.04; p =0.02) or peripheral joint involvement (OR 0.6, p =0.01) compared to healthy controls [20].

Beyond its effect on the innate immune system, 1, 25(OH)2D reduces pro-inflammatory T helper 1 and Th17 cell activity, decreasing the production of pro-inflammatory cytokines (i.e. interleukin 1, TNF- α, interleukin -6, and interleukin-17). Besides, 1,25(OH)2D acts on T regulatory cells and Th2 responses, raising blood levels of anti-inflammatory cytokines (e.g. IL-10) [9]. Taking into account its autocrine action, 1,25(OH)2D lowers the release of autoantibodies and immunoglobulins in the plasma, contributing to modulate autoimmune and autoinflammatory response in immune-mediated inflammatory disorders [9, 14, 21].

Give the aforementioned, vitamin D could play a role in immune reactions, impairing the interaction between pro- and anti-inflammatory cytokines, but these evidences come from cross sectional studies and had not been confirmed in genome-wide association studies [22]. Therefore, these speculations about the interplay between vitamin D, immune system and SpA need to be further investigated; randomized clinical trials are needed, possibly carried out during the early stages of the disease to control progression, or in the longstanding forms, to prevent disease flares.

Fig. (1). An overview of the effects of 25(OH)D on the cells of the immune system.


Several studies highlighted that vitamin D deficiency is more frequent in patients affected by SpA compared to the general population or healthy controls. In 161 SpA patients, 25(OH)D serum levels were found significantly lower compared with unaffected subjects [23]. In the French DESIR cohort, including more than 700 patients with a recent onset of inflammatory back pain suggestive of SpA, severe vitamin D deficiency was found in 11.7% of patients compared with 5% in the French population. A recent study describing the prevalence of vitamin D deficiency on the ASAS-COMOSPA cohort has been published. In this international cross-sectional study, vitamin D deficiency was observed in 51,2% of 1030 patients, who were not receiving vitamin D supplementation. This deficit was independently associated with the presence of sacroiliitis (OR=2.1 [95%CI 1.3; 3.3]) and seasonal variation (OR=1.88, [95%CI 1.2;2.9]); suggesting that vitamin D deficiency is related to more severe forms of SpAs and seasonal fluctuation. No relation was found between vitamin D levels and comorbidities [24].

Patients who had baseline serum levels of 25(OH)D lower than 20 ng/mL showed a significant association with X-ray sacroiliitis (104/358 vs 81/342, p <0.03), higher Ankylosing Spondylitis Disease Activity Score (ASDAS), and elevated Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (226/358 vs 193/342, p< 0.03), even when these results were adjusted for season or ethnicity. This trend between vitamin D deficiency and mean values of disease activity/severity scores was further confirmed during the two-year follow-up period [25]. Similarly, other cross-sectional studies confirmed such evidence in cohorts including population with different ethnicity [26, 27].

Conversely, opposite findings were shown in another study, which included 203 AS patients and 120 healthy controls. Authors did not report data indicating a poorer vitamin D status in AS subjects. Moreover, they found no relation between serum 25(OH)D levels and disease activity, seasonal dosing, and physical function [28]. Several studies are consistent with Klingberg and coauthor findings. Arends and colleagues evaluated one hundred and twenty-eight consecutive Dutch outpatients with active AS. They investigated the link between Bone Mineral Density (BMD), bone turnover markers (such as procollagen type 1 N-terminal peptide, osteocalcin, and bone resorption marker serum C-telopeptides of type I collagen), and vitamin D status. Furthermore, they assess clinical scores of disease activity and physical function in order to identify parameters that could be related to low BMD. According to their results, increased bone turnover, inflammation, and low vitamin D levels could play a role in the pathophysiology of osteoporosis observed in AS, but ESR, CRP, ASDAS, or Bath AS Functional Index were not significantly correlated with BMD T-scores [29].

Another study investigated the correlation between osteoporosis, vitamin D and disease activity in a hundred patients with AS compared to 58 healthy controls. AS subjects were further divided into two groups as with or without osteoporosis, according to lateral lumbar BMD values. Authors found that BASDAI scores were higher in the AS osteoporotic group, but the difference between AS osteoporotic, non osteoporotic and healthy controls was not statistically significant (p >0.05). Only the Bath Ankylosing Spondylitis Metrology Index (BASMI) scores were significantly higher in patients with osteoporosis (5.28±2.45 vs 4.00±2.46, p <0.05); on the other hand, there was non difference in terms of (Bath Ankylosing Spondylitis Functional Index (BASFI) scores (5.38±2.25 vs 4.86±1.97, p >0.05). In patients with AS, a negative correlation without statistical significance was noted between the serum 25(OH)D level and ESR, CRP levels determining disease activity (r=-0.181, and r=-0.095, p >0.05, respectively). However, no significant correlation was detected between 25(OH)D and BASDAI scores (r=0.011, P >0.05) [30].

These controversial results on the complex relationship between vitamin D deficiency and SpAs should be read in light of several confounding factors that need to be considered. Periodontal inflammation could be promoted by vitamin D deficiency, inducing citrullination of peptides such as vimentin, as demonstrated also in RA Fig. (2). According to some reports, citrullinated vimentin is associated with radiological disease progression even in SpAs [31] and vitamin D deficiency could be related to X-ray sacroiliitis [25]. Some authors linked vitamin D status with worse disease activity/severity; reciprocally, functional impairment and structural damage could worsen vitamin D deficiency by reducing sunlight exposure. In this perspective, lower serum vitamin D status could be the result of disease activity than a cause thereof.

Fig. (2). Potential interactions and interconnections between vitamin D deficiency and development, severity and structural damage of Spondyloarthritis.

One study detected a high prevalence of anti-htTG antibodies, a marker of celiac disease, in AS subjects, raising concerns on a possible risk of malabsorption-related low vitamin D levels [32]; in fact, subclinical intestinal inflammation is common in AS, about 40-60% according to earlier endoscopic studies [5, 33, 34]. Furthermore, disease activity scored by BASDAI is independently associated with gut inflammation in axial SpA [35] and inflamed gut macrophages produce IL-23, which is notably up-regulated in SpA, inducing Th-17 response in enthesis through a specific subset of T-cells [36]. Taking all these data together, malabsorption could contribute to worsening vitamin D deficiency.


In SpA, bone involvement is dual: on the one hand, trabecular bone resorption by osteoclasts is mediated by the effect of pro-inflammatory cytokines such as TNF on the RANK ligand pathway [37, 38]; on the other hand, the peculiar new bone formation of SpAs is most notably driven by Wnt signaling [39, 40], than by bone morphogenetic proteins [41], and transforming growth factor β [42]. A longitudinal study evaluated the possible role of Sclerostin (SOST), a potent Wnt inhibitor, during anti-TNFα therapy in 30 patient affected by AS. Authors reported that SOST levels significantly increased after 1 year of anti-TNFα therapy (60.5±32.7 vs 72.7±31.9, p <0.001), concomitantly with a gradual increase of spine bone mineral density (p <0.001), suggesting that SOST could underlie the persistent syndesmophyte formation reported in patients with AS [43]. It has been demonstrated that parathyroid hormone down-regulate SOST expression by osteocytes both locally [44] and in the serum [45]. Since vitamin D deficiency may cause secondary hyperparathyroidism, leading to increase bone loss, it could be reasonable to monitor and supplement vitamin D in SpA patients.


SpA patients, apart from musculoskeletal involvement, frequently suffer from other comorbidities, and this risk is higher in SpA than in the general population, especially for some specific disorders (e.g., cardiovascular diseases (CVD) and osteoporosis) [46-50]. Such an increased risk for SpA patients can be related to the therapies used to obtain disease control (i.e., Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), corticosteroids) and also by other variables often observed in patients with SpA (for example, metabolic syndrome, systemic inflammation). In addition, in AS and/or PsA, it has been described an excess of mortality [46-48] that can be related not only to an increased risk of CVD [51-53], but also to osteoporosis [54], mostly for the complications following vertebral fractures [55, 56].

5.1. Cardiovascular Risk

Vitamin D deficiency is associated with various vascular dysfunction such as arterial stiffening and left ventricular hypertrophy [57]. Moreover, low levels of vitamin D might be involved in worsening of diabetes, hypertension and hyperlipidemia control, with a consequent increase of cardiovascular morbidity and mortality [58, 59]. Some studies highlighted the inverse relationship between vitamin D deficiency and elevated blood pressure, suggesting a possible involvement of vitamin D metabolism in the pathogenesis of hypertension. Such effect on blood pressure could be explained by the key modulating effects of vitamin D on the renin-angiotensin aldosterone system; in fact, vitamin D deficiency may promote a sustained activation of this axis [60].

However, meta-analyses of clinical trials evaluating vitamin D supplementation failed their goals on CVD risk factor improvement [61-66]. Wang and coauthors published a meta-analysis of 17 prospective cohort studies and randomized trials. According to their findings, moderate to high doses of vitamin D supplements might reduce cardiovascular risk, especially for dialyzed patients [67]. Nevertheless, this evidence is quite poor; in fact, only one study involving the general population [68] showed a reduction in ischemic cardiovascular disease after vitamin D supplementation.

Cytokines in the boxes are pro-inflammatory cytokines, while asterisks are next to anti-inflammatory cytokines. Dashed arrows indicate decreased differentiation, and continue arrows indicate increased differentiation.

Periodontal inflammation could be promoted by vitamin D deficiency, inducing citrullination of peptides, which is associated with radiological disease progression in SpA. Vitamin D status can be the result of a worse disease activity/severity course; reciprocally, functional impairment and structural damage could worse vitamin D deficiency by reducing sunlight exposure. High frequency of silent inflammatory bowel disease are reported in SpA with a consequent risk of malabsorption, which could contribute in worsening vitamin D deficiency. In SpA, bone involvement is dual: on the one hand, trabecular bone resorption is stimulated by cytokines and RANK ligand pathway; on the other hand, the peculiar new bone formation is most notably driven by Wnt signaling.

It should be stressed that most of these trials on the therapeutic effect of vitamin D were designed to investigate protective skeletal effects on quite elderly people (mean age exceeded 70 years), mostly women, with established CVD or other risk factors [65]. To date, among the available randomized trials on cardiovascular outcomes, less than one-half were designed without predefined cardiovascular endpoint; so any inference could be misleading.

Controversial results suggest that the maintenance of ideal 25(OH)D levels may reduce the risk of stroke among a representative sample of the US population [69]. Besides, AS patients have 1.6-1.9 fold increased risk for cardiovascular diseases than the general population [7]. Beyond traditional CVD risk factors (i.e. smoking, obesity, dyslipidemia, hypertension), chronic inflammation can play as a further determinant.

5.2. Osteoporosis

Although new bone formation may be considered as a hallmark of AS, osteoporosis is a well-recognized comorbidity, which occurs even in the early, mild form of AS and increases the risk of fractures. Radiographic bone loss has already been recognized in pre-densitometric studies [70, 71], and osteoporosis was connected with disease duration and older age. Bone loss starts rapidly in AS, at the beginning of the disease, involving trabecular bone [72], as not only a consequence of spinal stiffness or immobility. As a direct consequence of osteoporosis, vertebral fractures are frequently reported in AS, even if they are underestimated in clinical practice, due to misinterpretation of back pain that could be wrongly attributed to exacerbations of the spondylitic process instead to the fractures [73]. Moreover, fractures are associated with severe consequences in term of skeletal pain, stiffness, disability, physical deformity, disability, poor quality of life, need for long-term care assistance, and, last but not the least, financial burden [74-76]. Moreover, vertebral fractures may cause severe neurologic consequences and even increased mortality [75]. Another challenge consists of the diagnosis and surgical management of such fractures, because these patients frequently have a pre-existing skeletal involvement and several comorbidities [77]. A recently published meta-analysis evaluated the risk factors of fractures in AS. Pray and coauthors demonstrated that the main risk factors of vertebral fractures in SA are male sex, disease duration, modified Stoke Ankylosing Spondylitis Spinal Score, Bath AS Radiology Index, and low BMD at the hip and distal forearm. To date, evidence on hip fracture risk in AS is inconsistent. Any inferences can be made regarding the effect of NSAIDs and TNF inhibitors on fracture risk, due to the lack of conclusive results [77].

As aforementioned, two opposite mechanisms affect bone metabolism in SpAs: a high incidence of osteoporosis and vertebral fracture risk and increased bone formation. Several factors can contribute to the high risk of osteoporosis and fractures, such as chronic inflammation, reduced motion or sedentary lifestyle due to pain and stiffness, or drug-induced osteoporosis [28, 29]. Vitamin D deficiency is a global health problem, as well as a common risk factor for osteoporosis. A most recent Cochrane analysis concluded on a reduction in hip and other fractures with low doses of vitamin D (about 10 μg daily) and calcium supplement [78]. According to a systematic review and meta-analyses of observational studies, the prevalence of osteoporosis varied from 11.7%-to 34% and from 11% to 24.6% for fractures in axial-spondyloarthritis patients. Furthermore, authors described a low 25(OH)D status in axial SpA cohort compared to controls, as a high corticosteroids use and alcohol intake [79]. Moreover, another cross-sectional study aimed to evaluate the relationship between disease activity, radiographic changes, bone mineral density, and vertebral fractures showed vitamin D deficiency in 85.7% of 206 axial SpA patients.

A concern regarding all data published in osteoporosis and SpA is that the anterior-posterior lumbar spine evaluation can overestimate BMD status by the presence of syndesmophytes, ligament calcifications, and fusion of facet joints [80, 81]. Moreover, the only hip BMD measure could not be sufficient to assess properly osteoporosis in all AS-patients since bone loss may primarily occur in the spine [29, 80].

Low vitamin D levels were significantly associated with the presence of fractures (20.8 vs 18.04, p=0.049) [82]. Taking all these data together, it seems fundamental to properly assess bone metabolism and fracture risk in spondyloarthritis.


Adequate vitamin D intake is pivotal for optimal balance of mineral and skeletal metabolism. Nowadays, the ideal serum level of25(OH)D that should be reached when treating with vitamin D supplements is still a matter of debate. According to different guidelines, 50 or 75 nmol/L (i.e. 20-30 ng/mL) could be considered the threshold [83-85]. Screening of vitamin D status is recommended in the population at risk for deficiency, for example, chronic kidney diseases, osteoporosis, malabsorption, some lymphomas, or in case of drugs interacting with vitamin D metabolism, such as steroids, cholestyramine, AIDS medications [83].

Moreover, it is still a matter of debate if the target of 25(OH)D supplementation strategy could be the increase of 25(OH)D plasma level; in fact, according to a retrospective analysis on an heterogeneous group of rheumatic diseases, a more efficient way of monitoring 25(OH)D serum concentration could be parathyroid hormone (PTH) suppression [86]. Furthermore, a strategy evaluating a loading dose supplementation, followed by a daily dose, seemed to be more effective in normalizing plasma 25(OH)D and suppressing PTH concentrations in patients with rheumatic diseases. Again, the same authors supported the evidence that patients with rheumatic diseases seem to be more refractory to PTH suppression by vitamin D supplementation, that is probably why they need higher doses compared to non-rheumatic subjects [87]. Thus, 25(OH)D treatment should aim to normalize vitamin D levels and decrease PTH concentrations [88].

Even though it seems to be logical to monitor vitamin D status in SpA patients, benefits from a therapeutic effect of vitamin supplementation appear to be very modest, especially in the absence of well-conducted clinical trials. In fact, no longitudinal intervention study, with accurate sample size and design, has been carried out; so, it could be very risky to over- or misinterpret results coming from case series, case reports or cross sectional studies. Considering the lack of incontrovertible data, it seems to be rational to monitor 25(OH)D levels in SpA subjects and to target vitamin D global health threshold Table 1.

Table 1. Vitamin D supplementation as recommended by the Endocrine Society for the treatment of vitamin D deficiency [84].
Age Dose
0-1 year 400-1000 IU/day
1-18 years 600-1000 IU/day
Adults 800-1000 IU/day
51-70 years 800 IU/day
>70 years 800 IU/day
Osteoporotic patients with serum vitamin D<50 nmol/L
Or <75 nmol/L in elderly with a high risk of falls and fractures
800-1000 IU/day
IU: international units


To conclude, latitude, season, clothing, skin pigmentation, time spent outdoor, and all the parameters related to UVB exposure are the most important determinants for serum 25(OH)D. Moreover, vitamin D metabolites are not easy to be dosed for several reasons. Given the above, a snapshot measurement of 25(OH)D without adjustment for or awareness of these confounding factors could mislead studies’ conclusions, introducing both bias and noise in cases and controls, making comparisons between countries complex. According to the literature data, patients affected by SpA seem to have lower 25(OH)D levels compared to healthy controls or general population. Moreover, several authors gave evidence for an inverse association between measures of disease activity and 25(OH)D levels. Studies were not completely in agreement about this issue and this discordance is not unexpected. In fact, all these data come from cross-sectional studies, which impairs the ability to infer causality. Indeed, SpA subjects suffer from an increased risk of osteoporosis. So far, realizing whether 25(OH)D is a risk factor for disease susceptibility is important, as a modification of levels may protect against disease development in at-risk individuals. Therefore, if vitamin D deficiency could predict a more severe disease, understanding this risk could lead to focus on new pathogenic mechanisms as well as cost-effective therapy approaches. Well-designed and well-executed studies are needed, in order to clarify vitamin D impact on several health issues, including the extra-skeletal effects of vitamin D deficiency. Large, randomized controlled clinical trials assessing the benefits of supplement vitamin D in SpA, outside the largely well-known skeleton effects, are still lacking.


Not applicable.


The authors declare no conflict of interest, financial or otherwise.


Declared None


[1] Dougados M, Baeten D. Spondyloarthritis. Lancet 2011; 377(9783): 2127-37.
[2] Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med 2016; 375(13): 1303.
[3] Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: A systematic review and meta-analysis. Ann Rheum Dis 2015; 74(1): 65-73.
[4] Essers I, Ramiro S, Stolwijk C, et al. Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS. Rheumatology (Oxford) 2015; 54(4): 633-40.
[5] Klingberg E, Lorentzon M, Mellström D, et al. Osteoporosis in ankylosing spondylitis - prevalence, risk factors and methods of assessment. Arthritis Res Ther 2012; 14(3): R108.
[6] Reynolds JA, Bruce IN. Vitamin D treatment for connective tissue diseases: Hope beyond the hype? Rheumatology (Oxford) 2017; 56(2): 178-86.
[7] Essouma M, Noubiap JJ. Is air pollution a risk factor for rheumatoid arthritis? J Inflamm (Lond) 2015; 12: 48.
[8] Holick MF. Vitamin D status: Measurement, interpretation, and clinical application. Ann Epidemiol 2009; 19(2): 73-8.
[9] Hewison M. Vitamin D and immune function: An overview. Proc Nutr Soc 2012; 71(1): 50-61.
[10] Bikle DD. What is new in vitamin D: 2006-2007. Curr Opin Rheumatol 2007; 19(4): 383-8.
[11] Wöbke TK, Sorg BL, Steinhilber D. Vitamin D in inflammatory diseases. Front Physiol 2014; 5: 244.
[12] Ponsonby AL, McMichael A, van der Mei I. Ultraviolet radiation and autoimmune disease: Insights from epidemiological research. Toxicology 2002; 181-182: 71-8.
[13] Braun-Moscovici Y, Toledano K, Markovits D, Rozin A, Nahir AM, Balbir-Gurman A. Vitamin D level: Is it related to disease activity in inflammatory joint disease? Rheumatol Int 2011; 31(4): 493-9.
[14] Arnson Y, Amital H, Shoenfeld Y. Vitamin D and autoimmunity: New aetiological and therapeutic considerations. Ann Rheum Dis 2007; 66(9): 1137-42.
[15] Helming L, Böse J, Ehrchen J, et al. 1alpha,25-Dihydroxyvitamin D3 is a potent suppressor of interferon gamma-mediated macrophage activation. Blood 2005; 106(13): 4351-8.
[16] Gatenby P, Lucas R, Swaminathan A. Vitamin D deficiency and risk for rheumatic diseases: An update. Curr Opin Rheumatol 2013; 25(2): 184-91.
[17] Steinwender G, Lindner E, Weger M, et al. Association between polymorphism of the vitamin D metabolism gene CYP27B1 and HLA-B27-associated uveitis. Is a state of relative immunodeficiency pathogenic in HLA B27-positive uveitis? PLoS One 2013; 8(4): e62244.
[18] Mitulescu TC, Stavaru C, Voinea LM, Banica LM, Matache C, Predeteanu D. The role of vitamin D in immuno-inflammatory responses in ankylosing spondylitis patients with and without Acute Anterior Uveitis. J Med Life 2016; 9(1): 26-33.
[19] Obermayer-Pietsch BM, Lange U, Tauber G, et al. Vitamin D receptor initiation codon polymorphism, bone density and inflammatory activity of patients with ankylosing spondylitis. Osteoporos Int 2003; 14(12): 995-1000.
[20] Jung KH, Kim TH, Sheen DH, et al. Associations of vitamin D binding protein gene polymorphisms with the development of peripheral arthritis and uveitis in ankylosing spondylitis. J Rheumatol 2011; 38(10): 2224-9.
[21] Zhao S, Duffield SJ, Moots RJ, Goodson NJ. Systematic review of association between vitamin D levels and susceptibility and disease activity of ankylosing spondylitis. Rheumatology (Oxford) 2014; 53(9): 1595-603.
[22] Cortes A, Hadler J, Pointon JP, et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet 2013; 45(7): 730-8.
[23] Erten S, Kucuksahin O, Sahin A, Altunoglu A, Akyol M, Koca C. Decreased plasma vitamin D levels in patients with undifferentiated spondyloarthritis and ankylosing spondylitis. Intern Med 2013; 52(3): 339-44.
[24] Fernandes S, Etcheto A, van der Heijde D, et al. Vitamin D status in spondyloarthritis: Results of the ASAS-COMOSPA international study. Clin Exp Rheumatol 2017.
[25] Hmamouchi I, Paternotte S, Molto A, et al. Vitamin D, disease activity and comorbidities in early spondyloarthritis. Clin Exp Rheumatol 2016; 34(3): 396-403.
[26] Durmus B, Altay Z, Baysal O, Ersoy Y. Does vitamin D affect disease severity in patients with ankylosing spondylitis? Chin Med J (Engl) 2012; 125(14): 2511-5.
[27] Yazmalar L, Ediz L, Alpayci M, Hiz O, Toprak M, Tekeoglu I. Seasonal disease activity and serum vitamin D levels in rheumatoid arthritis, ankylosing spondylitis and osteoarthritis. Afr Health Sci 2013; 13(1): 47-55.
[28] Klingberg E, Oleröd G, Hammarsten O, Forsblad-d’Elia H. The vitamin D status in ankylosing spondylitis in relation to intestinal inflammation, disease activity, and bone health: A cross-sectional study. Osteoporos Int 2016; 27(6): 2027-33.
[29] Arends S, Spoorenberg A, Bruyn GA, et al. The relation between bone mineral density, bone turnover markers, and vitamin D status in ankylosing spondylitis patients with active disease: a cross-sectional analysis. Osteoporos Int 2011; 22(5): 1431-9.
[30] Mermerci Başkan B, Pekin Doğan Y, Sivas F, Bodur H, Ozoran K. The relation between osteoporosis and vitamin D levels and disease activity in ankylosing spondylitis. Rheumatol Int 2010; 30(3): 375-81.
[31] Wendling D, Prati C. Spondyloarthritis and smoking: Towards a new insight into the disease. Expert Rev Clin Immunol 2013; 9(6): 511-6.
[32] Mawer EB. Vitamin D deficiency in patients with intestinal malabsorption. Nutrition 1997; 13(9): 814-5.
[33] Mielants H, Veys EM, Cuvelier C, et al. The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol 1995; 22(12): 2273-8.
[34] Leirisalo-Repo M, Turunen U, Stenman S, Helenius P, Seppälä K. High frequency of silent inflammatory bowel disease in spondylarthropathy. Arthritis Rheum 1994; 37(1): 23-31.
[35] Van Praet L, Van den Bosch FE, Jacques P, et al. Microscopic gut inflammation in axial spondyloarthritis: A multiparametric predictive model. Ann Rheum Dis 2013; 72(3): 414-7.
[36] Sherlock JP, Buckley CD, Cua DJ. The critical role of interleukin-23 in spondyloarthropathy. Mol Immunol 2014; 57(1): 38-43.
[37] Lukić IK, Grcević D, Kovacić N, et al. Alteration of newly induced endochondral bone formation in adult mice without tumour necrosis factor receptor 1. Clin Exp Immunol 2005; 139(2): 236-44.
[38] Kim HR, Lee SH, Kim HY. Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with Ankylosing Spondylitis (AS). Rheumatology (Oxford) 2006; 45(10): 1197-200.
[39] Appel H, Ruiz-Heiland G, Listing J, et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 2009; 60(11): 3257-62.
[40] Haynes KR, Pettit AR, Duan R, et al. Excessive bone formation in a mouse model of ankylosing spondylitis is associated with decreases in Wnt pathway inhibitors. Arthritis Res Ther 2012; 14(6): R253.
[41] Lories RJ, Luyten FP. Bone morphogenetic proteins in destructive and remodeling arthritis. Arthritis Res Ther 2007; 9(2): 207.
[42] Lories RJ, Derese I, de Bari C, Luyten FP. Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthritis Rheum 2007; 56(2): 489-97.
[43] Saad CG, Ribeiro AC, Moraes JC, et al. Low sclerostin levels: A predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy? Arthritis Res Ther 2012; 14(5): R216.
[44] Bellido T, Ali AA, Gubrij I, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: A novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005; 146(11): 4577-83.
[45] Drake MT, Srinivasan B, Mödder UI, et al. Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 2010; 95(11): 5056-62.
[46] Bremander A, Petersson IF, Bergman S, Englund M. Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res (Hoboken) 2011; 63(4): 550-6.
[47] Prati C, Claudepierre P, Pham T, Wendling D. Mortality in spondylarthritis. Joint Bone Spine 2011; 78(5): 466-70.
[48] Gladman DD. Mortality in psoriatic arthritis. Clin Exp Rheumatol 2008; 26(5)(Suppl. 51): S62-5.
[49] Moltó A, Etcheto A, van der Heijde D, et al. Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: Results of the international cross-sectional ASAS-COMOSPA study. Ann Rheum Dis 2016; 75(6): 1016-23.
[50] Essers I, Stolwijk C, Boonen A, et al. Ankylosing spondylitis and risk of ischaemic heart disease: A population-based cohort study. Ann Rheum Dis 2016; 75(1): 203-9.
[51] Sari I, Okan T, Akar S, et al. Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology (Oxford) 2006; 45(3): 283-6.
[52] Peters MJ, van Eijk IC, Smulders YM, et al. Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 2010; 37(1): 161-6.
[53] Mathieu S, Gossec L, Dougados M, Soubrier M. Cardiovascular profile in ankylosing spondylitis: A systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2011; 63(4): 557-63.
[54] Briot K, Garnero P, Le Henanff A, Dougados M, Roux C. Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor alpha treatment. Ann Rheum Dis 2005; 64(8): 1137-40.
[55] Westerveld LA, Verlaan JJ, Oner FC. Spinal fractures in patients with ankylosing spinal disorders: A systematic review of the literature on treatment, neurological status and complications. Eur Spine J 2009; 18(2): 145-56.
[56] Verlaan JJ, Diekerhof CH, Buskens E, et al. Surgical treatment of traumatic fractures of the thoracic and lumbar spine: A systematic review of the literature on techniques, complications, and outcome. Spine 2004; 29(7): 803-14.
[57] Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117(4): 503-11.
[58] Pittas AG, Chung M, Trikalinos T, et al. Systematic review: Vitamin D and cardiometabolic outcomes. Ann Intern Med 2010; 152(5): 307-14.
[59] Al Mheid I, Patel RS, Tangpricha V, Quyyumi AA. Vitamin D and cardiovascular disease: Is the evidence solid? Eur Heart J 2013; 34(48): 3691-8.
[60] Vaidya A, Sun B, Larson C, Forman JP, Williams JS. Vitamin D3 therapy corrects the tissue sensitivity to angiotensin ii akin to the action of a converting enzyme inhibitor in obese hypertensives: An interventional study. J Clin Endocrinol Metab 2012; 97(7): 2456-65.
[61] Joris PJ, Mensink RP. Effects of supplementation with the fat-soluble vitamins E and D on fasting flow-mediated vasodilation in adults: A meta-analysis of randomized controlled trials. Nutrients 2015; 7(3): 1728-43.
[62] Rodríguez AJ, Scott D, Srikanth V, Ebeling P. Effect of vitamin D supplementation on measures of arterial stiffness: A systematic review and meta-analysis of randomized controlled trials. Clin Endocrinol (Oxf) 2016; 84(5): 645-57.
[63] Stojanović M, Radenković M. Vitamin D versus placebo in improvement of endothelial dysfunction: A meta-analysis of randomized clinical trials. Cardiovasc Ther 2015; 33(3): 145-54.
[64] Bolland MJ, Grey A, Gamble GD, Reid IR. Calcium and vitamin D supplements and health outcomes: A reanalysis of the Women’s Health Initiative (WHI) limited-access data set. Am J Clin Nutr 2011; 94(4): 1144-9.
[65] Bjelakovic G, Gluud LL, Nikolova D, et al. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev 2011; (7): CD007470.
[66] Al Mheid I, Quyyumi AA. Vitamin D and cardiovascular disease: Controversy unresolved. J Am Coll Cardiol 2017; 70(1): 89-100.
[67] Wang L, Manson JE, Song Y, Sesso HD. Systematic review: Vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med 2010; 152(5): 315-23.
[68] Bostick RM, Kushi LH, Wu Y, Meyer KA, Sellers TA, Folsom AR. Relation of calcium, vitamin D, and dairy food intake to ischemic heart disease mortality among postmenopausal women. Am J Epidemiol 1999; 149(2): 151-61.
[69] Li J, Lai H, Yang L, Zhu H, Chen S, Lai S. Age and gender differences in the association between serum 25-Hydroxyvitamin D and stroke in the general US population: The national health and nutrition examination survey, 2001-2006. J Stroke Cerebrovasc Dis 2017; 26(11): 2510-8.
[70] Hanson CA, Shagrin JW, Duncan H. Vertebral osteoporosis in ankylosing spondylitis. Clin Orthop Relat Res 1971; 74(74): 59-64.
[71] Will R, Palmer R, Bhalla AK, Ring F, Calin A. Osteoporosis in early ankylosing spondylitis: A primary pathological event? Lancet 1989; 2(8678-8679): 1483-5.
[72] Lee YS, Schlotzhauer T, Ott SM, et al. Skeletal status of men with early and late ankylosing spondylitis. Am J Med 1997; 103(3): 233-41.
[73] Sinigaglia L, Varenna M, Girasole G, Bianchi G. Epidemiology of osteoporosis in rheumatic diseases. Rheum Dis Clin North Am 2006; 32(4): 631-58.
[74] Feldtkeller E, Vosse D, Geusens P, van der Linden S. Prevalence and annual incidence of vertebral fractures in patients with ankylosing spondylitis. Rheumatol Int 2006; 26(3): 234-9.
[75] Schiefer TK, Milligan BD, Bracken CD, et al. In-hospital neurologic deterioration following fractures of the ankylosed spine: A single-institution experience. World Neurosurg 2015; 83(5): 775-83.
[76] Ralston SH, Urquhart GD, Brzeski M, Sturrock RD. Prevalence of vertebral compression fractures due to osteoporosis in ankylosing spondylitis. BMJ 1990; 300(6724): 563-5.
[77] Pray C, Feroz NI, Nigil Haroon N. Bone mineral density and fracture risk in ankylosing spondylitis: A meta-analysis. Calcif Tissue Int 2017; 101(2): 182-92.
[78] Avenell A, Mak JC, O’Connell D. Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men. Cochrane Database Syst Rev 2014; (4): CD000227.
[79] Ramírez García J, Curbelo R, Nieto JC, Castañeda S, Carmona L. Prevalence and risk factors for osteoporotic fractures and low bone mineral density in axial spondyloarthritis: A systematic review and meta-analysis. Ann Rheum Dis 2017; 76(Suppl. 2): 1305.
[80] Baek HJ, Kang SW, Lee YJ, et al. Osteopenia in men with mild and severe ankylosing spondylitis. Rheumatol Int 2005; 26(1): 30-4.
[81] Meirelles ES, Borelli A, Camargo OP. Influence of disease activity and chronicity on ankylosing spondylitis bone mass loss. Clin Rheumatol 1999; 18(5): 364-8.
[82] Romera-López C, Fernández-Carballido C, García-Moreno MÁ, Pedraz T. Osteoporosis and Vertebral Fractures Are Associated with Disease Activity, Low Vitamin D Levels and Spinal Radiographic Damage in Patients with Axial Spondyloarthritis. Arthritis Rheumatol 2017; 69((suppl 10)).
[83] Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J Clin Endocrinol Metab 2012; 97(4): 1153-8.
[84] Rizzoli R, Boonen S, Brandi ML, et al. Vitamin D supplementation in elderly or postmenopausal women: A 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Curr Med Res Opin 2013; 29(4): 305-13.
[85] Bischoff-Ferrari HA, Willett WC, Orav EJ, et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med 2012; 367(1): 40-9.
[86] Sainaghi PP, Bellan M, Nerviani A, et al. Superiority of a high loading dose of cholecalciferol to correct hypovitaminosis d in patients with inflammatory/autoimmune rheumatic diseases. J Rheumatol 2013; 40(2): 166-72.
[87] Sainaghi PP, Bellan M, Carda S, et al. Hypovitaminosis D and response to cholecalciferol supplementation in patients with autoimmune and non-autoimmune rheumatic diseases. Rheumatol Int 2012; 32(11): 3365-72.
[88] Sainaghi PP, Bellan M, Antonini G, Bellomo G, Pirisi M. Unsuppressed parathyroid hormone in patients with autoimmune/inflammatory rheumatic diseases: Implications for vitamin D supplementation. Rheumatology (Oxford) 2011; 50(12): 2290-6.